Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Based on the investigator's previous data on risk classification for acute leukemia,the investigators will design a set of panels to detect the gene expression and genomic variants (SNPs, mutation, insertion, deletion and fusion genes, etc), and identify the high-risk subtypes of acute leukemia, such as Ph-like acute lymphoblastic leukemia. Furthermore, the target therapy (Tyrosine Kinase Inhibitors,et.al) will be used to treat the identified patients. In addition, more sensitive minimal residual disease (MRD) detection technology will be designed and used to detect the MRD in patients to early predict the disease relapse.
patient eligibility criteria: newly diagnosed acute leukemia patients with clinical high-risk markers, reflactory and relapsed patients.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| high-risk group | Selected by "High-risk subtype detection panels" |
| |
| non high-risk group | Selected by "High-risk subtype detection panels" |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| High-risk subtype detection panels | Diagnostic Test | The designed detection technology were used to identify the high-risk patients cohort. |
|
| Measure | Description | Time Frame |
|---|---|---|
| complete remission | Patients achieve complete remission after initial treatment | From date of randomization or initial treatment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months |
| relapse | Patients' disease progress after complete remission | From date of randomization or complete remission until the date of first documented relapse from any cause, whichever came first, assessed up to 100 weeks |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
patients with acute leukemia (newly diagnosis)
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Department of Hematology, Zhongda Hospital Southeast University, Institute of Hematology Southeast University | Nanjing | Jiangsu | 210009 | China |
Not provided
| ID | Term |
|---|---|
| D007938 | Leukemia |
| ID | Term |
|---|---|
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
| D006402 | Hematologic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Patients' samples from bone marrow